CCTV net news: the new year, see a doctor medication also have good news. The Office of Centralized Drug Purchase and Use of the State Organization has issued a national centralized drug purchase document,33 varieties have been selected as the second batch of national centralized drug purchase list, and another wave of reduced prices of drugs has been \"on the way.\"
The second batch of national drug centralized purchase list covers hypertension, diabetes and other major chronic diseases, as well as anti-tumor and rare disease drugs. According to the purchase catalogue, acarbose and other oral hypoglycemic drugs; omesartan ester and other hypertension drugs; treatment of rare diseases-pulmonary arterial hypertension drugs anlishengtan tablets, as well as anti-cancer drugs tegeo, abitron and other drugs shortlisted.
According to the centralized procurement work arrangement, the bid opening will produce the result of the proposed selection on January 17,2020, and patients from all over the country will use the second batch of concentrated belt quantity to purchase the selected drugs in April this year.
Some of the self-financed varieties that are not included in the health care catalogue are also joining the centralized purchase this time. Industry insiders point out that this means that self-financed medicines will also feel the \"pressure\" to reduce prices brought on by concentrated purchases.
It has become a trend to guide the price reduction of drugs by the mode of purchasing with quantity. Recently, more than 50,000 small and medium-sized pharmacies across the country formed an alliance to achieve \"quantity-for-price\" through sales volume of national retail pharmacies and negotiations among pharmaceutical enterprises, and to reduce the price of drugs sold in pharmacies. Let common people take cheap rest assured medicine, let drugstore obtain scale and profit double growth, promote the implementation process of medicine separation in an all-round way.